Evidence map›Paper›PMID 30341715›Full record

ReviewClinical journal of gastroenterology2019

Occurrence of hepatocellular carcinoma 24 years after successful interferon therapy in a patient with chronic hepatitis C: a case report.

Yuichi Yoshida, Miki Yonezawa, Takuya Okamoto, Yudai Fujiwara, Akiko Suzuki, Yuji Suzuki, Kei Endo, Keisuke Kakisaka, Takayoshi Oikawa, Hidekatsu Kuroda and 2 more

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Clinical journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuichi YoshidaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-9 Uchimaru, Morioka, Iwate, Japan. yoshiday@iwate-med.ac.jp.ORCID http://orcid.org/0000-0001-8855-4099
Miki YonezawaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-9 Uchimaru, Morioka, Iwate, Japan.
Takuya OkamotoDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-9 Uchimaru, Morioka, Iwate, Japan.
Yudai FujiwaraDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-9 Uchimaru, Morioka, Iwate, Japan.
Akiko SuzukiDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-9 Uchimaru, Morioka, Iwate, Japan.
Yuji SuzukiDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-9 Uchimaru, Morioka, Iwate, Japan.
Kei EndoDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-9 Uchimaru, Morioka, Iwate, Japan.
Keisuke KakisakaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-9 Uchimaru, Morioka, Iwate, Japan.
Takayoshi OikawaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-9 Uchimaru, Morioka, Iwate, Japan.
Hidekatsu KurodaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-9 Uchimaru, Morioka, Iwate, Japan.
Akio MiyasakaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-9 Uchimaru, Morioka, Iwate, Japan.
Yasuhiro TakikawaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-9 Uchimaru, Morioka, Iwate, Japan.

Funding

Ministry of Health, Labour and Welfare H28-kansei-ippan-001
6 · The paper itself

Abstract

An 82-year-old man presented with hepatocellular carcinomas (HCCs) 24 years after achieving a sustained virological response (SVR) to an interferon for hepatitis C. His hepatic fibrosis stage was F1 when he was treated at 58 years. He was followed-up by annual blood tests and abdominal ultrasonography or computed tomography. After the IFN treatment, he had drunk approximately 100 g of ethanol. Serum aspartate aminotransferase and gamma-glutamyl transpeptidase levels had been elevated since 2012. To investigate the possible factors that affect hepatocarcinogenesis over 10 years after achieving an SVR, we reviewed the literature. Of 39 reported patients, 26, as well as ours, had one or more lifestyle-related factors, including body mass index ≥ 25 kg/m

Indexed as

Aged, 80 and overAge FactorsAlcoholismAntiviral AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticHepatitis C, ChronicHumansInterferonsLiver NeoplasmsMaleRisk FactorsSustained Virologic ResponseTime FactorsAntiviral AgentsInterferonsAlcohol consumptionBody mass indexDiabetes mellitusHepatosteatosisSustained virological response

Identifiers

PMID30341715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.